First Time Loading...

BridgeBio Pharma Inc
NASDAQ:BBIO

Watchlist Manager
BridgeBio Pharma Inc Logo
BridgeBio Pharma Inc
NASDAQ:BBIO
Watchlist
Price: 25.77 USD -3.95% Market Closed
Updated: Apr 16, 2024

Intrinsic Value

BBIO's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. [ Read More ]

The intrinsic value of one BBIO stock under the Base Case scenario is 31.18 USD. Compared to the current market price of 25.77 USD, BridgeBio Pharma Inc is Undervalued by 17%.

Key Points:
BBIO Intrinsic Value
Base Case
31.18 USD
Undervaluation 17%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
BridgeBio Pharma Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling BBIO stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
BridgeBio Pharma Inc

Provide an overview of the primary business activities
of BridgeBio Pharma Inc.

What unique competitive advantages
does BridgeBio Pharma Inc hold over its rivals?

What risks and challenges
does BridgeBio Pharma Inc face in the near future?

Has there been any significant insider trading activity
in BridgeBio Pharma Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for BridgeBio Pharma Inc.

Provide P/S
for BridgeBio Pharma Inc.

Provide P/E
for BridgeBio Pharma Inc.

Provide P/OCF
for BridgeBio Pharma Inc.

Provide P/FCFE
for BridgeBio Pharma Inc.

Provide P/B
for BridgeBio Pharma Inc.

Provide EV/S
for BridgeBio Pharma Inc.

Provide EV/GP
for BridgeBio Pharma Inc.

Provide EV/EBITDA
for BridgeBio Pharma Inc.

Provide EV/EBIT
for BridgeBio Pharma Inc.

Provide EV/OCF
for BridgeBio Pharma Inc.

Provide EV/FCFF
for BridgeBio Pharma Inc.

Provide EV/IC
for BridgeBio Pharma Inc.

Show me price targets
for BridgeBio Pharma Inc made by professional analysts.

What are the Revenue projections
for BridgeBio Pharma Inc?

How accurate were the past Revenue estimates
for BridgeBio Pharma Inc?

What are the Net Income projections
for BridgeBio Pharma Inc?

How accurate were the past Net Income estimates
for BridgeBio Pharma Inc?

What are the EPS projections
for BridgeBio Pharma Inc?

How accurate were the past EPS estimates
for BridgeBio Pharma Inc?

What are the EBIT projections
for BridgeBio Pharma Inc?

How accurate were the past EBIT estimates
for BridgeBio Pharma Inc?

Compare the revenue forecasts
for BridgeBio Pharma Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of BridgeBio Pharma Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of BridgeBio Pharma Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of BridgeBio Pharma Inc compared to its peers.

Compare the P/E ratios
of BridgeBio Pharma Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing BridgeBio Pharma Inc with its peers.

Analyze the financial leverage
of BridgeBio Pharma Inc compared to its main competitors.

Show all profitability ratios
for BridgeBio Pharma Inc.

Provide ROE
for BridgeBio Pharma Inc.

Provide ROA
for BridgeBio Pharma Inc.

Provide ROIC
for BridgeBio Pharma Inc.

Provide ROCE
for BridgeBio Pharma Inc.

Provide Gross Margin
for BridgeBio Pharma Inc.

Provide Operating Margin
for BridgeBio Pharma Inc.

Provide Net Margin
for BridgeBio Pharma Inc.

Provide FCF Margin
for BridgeBio Pharma Inc.

Show all solvency ratios
for BridgeBio Pharma Inc.

Provide D/E Ratio
for BridgeBio Pharma Inc.

Provide D/A Ratio
for BridgeBio Pharma Inc.

Provide Interest Coverage Ratio
for BridgeBio Pharma Inc.

Provide Altman Z-Score Ratio
for BridgeBio Pharma Inc.

Provide Quick Ratio
for BridgeBio Pharma Inc.

Provide Current Ratio
for BridgeBio Pharma Inc.

Provide Cash Ratio
for BridgeBio Pharma Inc.

What is the historical Revenue growth
over the last 5 years for BridgeBio Pharma Inc?

What is the historical Net Income growth
over the last 5 years for BridgeBio Pharma Inc?

What is the current Free Cash Flow
of BridgeBio Pharma Inc?

AI Assistant can make mistakes. Consider checking important information.
Financials

Balance Sheet Decomposition
BridgeBio Pharma Inc

Current Assets 418.6m
Cash & Short-Term Investments 375.9m
Other Current Assets 42.7m
Non-Current Assets 127.7m
Long-Term Investments 58.9m
PP&E 19.8m
Intangibles 26.3m
Other Non-Current Assets 22.6m
Current Liabilities 139.7m
Accounts Payable 10.7m
Accrued Liabilities 129.1m
Non-Current Liabilities 1.8B
Long-Term Debt 1.7B
Other Non-Current Liabilities 34.2m
Efficiency

Earnings Waterfall
BridgeBio Pharma Inc

Revenue
9.3m USD
Operating Expenses
-608.7m USD
Operating Income
-599.4m USD
Other Expenses
-43.8m USD
Net Income
-643.2m USD

Free Cash Flow Analysis
BridgeBio Pharma Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

BBIO Profitability Score
Profitability Due Diligence

BridgeBio Pharma Inc's profitability score is 42/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Exceptional Revenue Growth Forecast
Exceptional ROE
ROIC is Increasing
42/100
Profitability
Score

BridgeBio Pharma Inc's profitability score is 42/100. The higher the profitability score, the more profitable the company is.

BBIO Solvency Score
Solvency Due Diligence

BridgeBio Pharma Inc's solvency score is 43/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Positive Net Debt
Long-Term Solvency
43/100
Solvency
Score

BridgeBio Pharma Inc's solvency score is 43/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BBIO Price Targets Summary
BridgeBio Pharma Inc

Wall Street analysts forecast BBIO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BBIO is 49.98 USD with a low forecast of 33.33 USD and a high forecast of 73.5 USD.

Lowest
Price Target
33.33 USD
29% Upside
Average
Price Target
49.98 USD
94% Upside
Highest
Price Target
73.5 USD
185% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

BBIO Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

BBIO Price
BridgeBio Pharma Inc

1M 1M
-7%
6M 6M
-1%
1Y 1Y
+71%
3Y 3Y
-53%
5Y 5Y
-6%
10Y 10Y
-6%
Annual Price Range
25.77
52w Low
13.29
52w High
43.89
Price Metrics
Average Annual Return -4.78%
Standard Deviation of Annual Returns 76.25%
Max Drawdown -93%
Shares Statistics
Market Capitalization 4.5B USD
Shares Outstanding 184 452 000
Percentage of Shares Shorted 12.19%

BBIO Return Decomposition
Main factors of price return

What is price return decomposition?

BBIO News

Other Videos

Last Important Events
BridgeBio Pharma Inc

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
BridgeBio Pharma Inc

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

BridgeBio Pharma Inc Logo
BridgeBio Pharma Inc

Country

United States of America

Industry

Biotechnology

Market Cap

4.5B USD

Dividend Yield

0%

Description

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. The company is headquartered in Palo Alto, California and currently employs 576 full-time employees. The company went IPO on 2019-06-27. The Company’s product platform divided into three key categories: Mendelian, Oncology and Gene therapy. The Company’s pipeline programs include product candidates ranging from early discovery to late-stage development. The Company’s products include BBP-561, BBP-711, BBP-631 and BBP-454.

Contact

CALIFORNIA
Palo Alto
c/o BridgeBio Pharma, Inc., 42 Kipling Street
+16503919740.0
http://bridgebio.com/

IPO

2019-06-27

Employees

576

Officers

Co-Founder, President, CEO & Director
Dr. Neil Kumar Ph.D.
Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director
Dr. Charles J. Homcy M.D.
CFO & Secretary
Dr. Brian C. Stephenson C.F.A., Ph.D.
Chairman of Research & Development
Dr. Richard H. Scheller Ph.D.
Co-Founder, Chairman of Oncology & Director
Dr. Frank P. McCormick Ph.D.
Chief Scientific Officer
Dr. Uma Sinha Ph.D.
Show More
Vice President of Communications
Grace Rauh
Chief Scientific Officer of Oncology
Mr. Eli M. Wallace Ph.D.
Chief Product Officer
Dr. Thomas Trimarchi Ph.D.
Chief Executive Officer of Gene Therapy
Dr. Eric Michael David J.D., M.D., Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one BBIO stock?

The intrinsic value of one BBIO stock under the Base Case scenario is 31.18 USD.

Is BBIO stock undervalued or overvalued?

Compared to the current market price of 25.77 USD, BridgeBio Pharma Inc is Undervalued by 17%.